https://www.selleckchem.com/pr....oducts/slf1081851-hy
We demonstrate that increased MET expression in fusion-positive tumor cells causes resistance to selpercatinib, and this can be overcome by combining selpercatinib with crizotinib. Using SPPs, selpercatinib with crizotinib were given together generating anecdotal evidence of clinical activity and tolerability, with one response lasting 10 months. Through the use of SPPs, we were able to offer combination therapy targeting -amplified resistance identified on the first-in-human study of selpercatinib. These data suggest t
Like
Comment
Share
